Nicotinic AChRs are found in the central, as well as the peripheral, nervous system, particularly in hippocampus, hypothalamus, midbrain and cerebral cortex. Lesion and pharmacological studies in animals and the effects of centrally-acting anticholinergic drugs in man have demonstrated that the central cholinergic system is important in mediating cognitive processes of learning and memory. Further impetus has been given to this research by the discovery in Alzheimer's disease of impaired cortical cholinergic innervation,6 which has been invoked as the mechanism responsible for the pattern of amnesic deficits seen in this condition. The amnesic effect of anticholinergic agents has been well replicated, but it remains unclear at which
SUMMARY Sporadic reports have suggested central involvement in myasthenia gravis, a disorder in which there is an antibody-mediated loss ofperipheral nicotinic acetylcholine receptors. Five patients with symptomatic myasthenia gravis performed an auditory vigilance test of ability to direct and sustain attention, presumed to reflect central cholinergic function. No deficits were found, either in comparison with the same subject's performance when muscle strength had improved after plasma exchange, or compared with that ofhealthy controls. The results thus failed to substantiate reports of functionally significant central cholinergic deficits in myasthenia gravis.
Myasthenia gravis is characterised by abnormal fatiguability of voluntary muscle that results from a reduced number of functional nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction. Receptor loss is caused by IgG anti-AChR autoantibodies,' and these antibodies can be detected in serum in 85-90% of cases.2 Treatment includes the use of acetylcholinesterase-inhibiting drugs which increase the availability of acetylcholine at the receptor, thymectomy and immunosuppressive drugs such as corticosteroids or azathioprine. In refractory cases, plasma exchange brings temporary symptomatic improvement.35
Nicotinic AChRs are found in the central, as well as the peripheral, nervous system, particularly in hippocampus, hypothalamus, midbrain and cerebral cortex. Lesion and pharmacological studies in animals and the effects of centrally-acting anticholinergic drugs in man have demonstrated that the central cholinergic system is important in mediating cognitive processes of learning and memory. Further impetus has been given to this research by the discovery in Alzheimer's disease of impaired cortical cholinergic innervation,6 which has been invoked as the mechanism responsible for the pattern of amnesic deficits seen in this condition. The amnesic effect of anticholinergic agents has been well replicated, but it remains unclear at which stage the primary disruption to information processing occurs.
Central The test sessions were given in the afternoon or early evening in a quiet room. Elicitation of physical symptoms and signs was followed by grip strength testing. In the first session, the Beck and cognitive questionnaire was then given; in the second session the NART. The auditory vigilance task was then given, preceded by taped instructions and confirmation that the subject understood the task. In order to control for any practice effects which might contribute to improvement in performance of myasthenia gravis subjects on retesting, control subjects were also retested after a period of 4 days. Performances of myasthenia gravis subjects and controls on the first and second test sessions were analysed in two ways according to the study's hypothesis: (a) For the controls, the mean number of correct "hits" in the first test session, out of a possible 100, was 52-3 (SD 9 1), rising to 60-4 (SD 12-7) at the second session 3 days later. This improvement in performance between sessions was presumably due to a practice effect, and was significant on a t test of mean within-subject differences (t = 4-2 (df = 7); p < 0.01).
For the myasthenia gravis subjects, the mean number of correct hits was 45 8 (SD 6-5) at the first session and 58 8 (SD at the second, posttreatment session. This mean improvement was not significant (t = 1-7 (df = 4); NS). This improvement in performance between sessions was more variable in the myasthenia gravis subjects (range of improvement + 0 to + 42) than in the controls (range of improvement + 2 to + 17).
The mean number of "errors" (responses in the absence ofa target triad) was similarly small for all test sessions, not exceeding 6 for myasthenia gravis subjects or controls.
(b) The main hypothesis of the study was that any reversible impairment in central cholinergic function in myasthenia gravis would be reflected in an inability to sustain attention over time, itself reversible by treatment. To obtain a measure of the degree to which subjects were able to sustain attention, the proportion of correct hits during the first 40% (6 minutes) of the test session was compared to that in the last 40%, before and after treatment.
Significant decline in mean performance during Lewis, Ron; Newsom-Davis 
Discussion
This study of cognitive function in myasthenia gravis failed to demonstrate deficits suggestive of impaired central cholinergic transmission. The ability to direct and sustain attention was measured using an auditory vigilance task in five young patients with moderately severe myasthenia gravis before and after treatment with plasma exchange. Despite clinical evidence of impaired peripheral cholinergic transmission, reversed by treatment, the myasthenia gravis subjects showed no absolute performance deficit, nor a decline in performance over time, when compared with either their own performance after treatment, or with that of healthy controls.
In view ofthe negative results, the validity ofthe test chosen to assess central cholinergic function merits discussion. Much experimental work has concerned the role of cholinergic pathways in human cognition. However, a clear consensus of opinion has been slow !1;
Absence ofcentralfunctional cholinergic deficits in myasthenia gravis to emerge. It is well replicated that anticholinergic agents such as hyoscine have amnesic effects, but the cognitive mechanism by which these are brought about is disputed. Frith et al '9 concluded that their work "suggests a cholinergic mechanism in the encoding of new information into long-term storage", supporting the interpretation that cholinergic activity is crucial in the transfer of information from primary into secondary memory.20 However, diazepam with little anticholinergic activity similarly disrupts the acquisition (rather than the retention or recall) phase of learning, and differences between the cognitive effects ofthe two types ofdrugs have not been shown. '9 The alternative view, increasingly supported by experimental data, is that cholinergic mechanisms are primarily involved in processes of attention rather than memory. Studies using search and vigilance tasks suggest that anticholinergic drugs specifically impair the direction'5 and maintenance'4 of selective attention. Thus, the detrimental effect of such drugs on memory is secondary to an attentional deficit which allows the intrusion of irrelevant, usually unattended stimuli. The choice of test in the present study was made on the basis ofthis evidence as well as the pattern of the peripheral impairment due to cholinergic deficits seen clinically in myasthenia gravis: that of "fatiguability". These considerations suggested that a dynamic test of attention over time was the most valid measure of central cholinergic activity, directly analogous to that used by Wesnes and Warburton. '4 It is important to note (table) that all myasthenia gravis subjects were taking maintenance medication at the time of testing. In particular, anticholinesterase agents such as physostigmine can enhance certain cognitive, mnemonic processes2' just as anticholinergic agents disrupt them, and would presumably act to offset any cognitive deficit in myasthenia gravis. However, the myasthenia gravis subjects in this study displayed 
